Incubate Coalition

Excited to be part of the breakfast conversation with Incubate Coalition and John Stanford, Tim Scott and Michelle Rozo! And always a treat to hear from NC’s own Senator Richard Burr!

At #JPM26 next week? Don’t miss our #JPMHangout event for a chance to network IRL with the biotech community at Persona (685 Sutter St.) from 7-10pm – all are welcome but please RSVP!   Thanks to our Gold Badge Sponsors CFGO, Syneos Health Communications, Incubate Coalition, and our Blue Badge Sponsors, FTI Consulting, Catalytic Agency, and Mispro, there will be free drinks at the event.    Register here: https://lnkd.in/ePU7-zzB

Pumped to be back in San Francisco for JPM, and especially for what’s shaping up to be our biggest and best policy breakfast yet. I’ll be moderating conversations with an incredible lineup of leaders from across policy, investing, trade, and industry — including Senator Richard Burr, Philip Hogan, Sara Nayeem, Rena Rosenberg, PhD, Marc Spencer Appel, Laura Gunter, Tim Scott, Michelle Rozo, Nina Kjellson, and Kirsten Axelsen — as we dig into what MFN, price controls, global competition, and political uncertainty really mean for the future of innovation. We’ll also be sharing fresh investor sentiment data and hearing directly from the people building and backing the next generation of therapies. Be sure to arrive early - this one will fill up fast. The whole Incubate Coalition team will be on the ground throughout the week — and we’re also bringing back Incubate Shorts, our quick-hit conversations with founders, investors, and policy leaders recorded onsite at JPM. Sign up here: https://lnkd.in/gBH8K7sh Mostly, I’m excited to reconnect with friends and colleagues across the industry and kick off the week with real conversation — not just hallway chatter. If you’d like to grab a coffee or a nightcap while you’re in town, send a note! #JPM2026 #biotech #innovation #policy #biopharma #venturecapital #lifesciences

🚀 Headed to JPM 2026? Join us for Innovation at a Crossroads: Biopharma Policy in an Era of Global Competition — our annual policy breakfast on January 12, co-hosted by Incubate and DLA Piper. We’ll dig into pricing, global competitiveness, FDA clarity, and what it all means for early-stage biotech. 👉 Register here: https://lnkd.in/ggYPg3Y5 🎙️ We’re also bringing back Incubate Shorts — quick, 15-minute conversations recorded onsite at JPM. 📅 Grab a recording slot: https://lnkd.in/gNcfe_E4 See you in San Francisco! John Stanford John Guy Grace Moster #JPM2026 #Biotech #Policy #Venture #IncubateCoalition

Today, the Center for Medicare and Medicaid Innovation (CMMI) announced proposed Medicare drug pricing demonstrations that would effectively impose Most Favored Nation–style price controls across broad categories of Part B and Part D medicines. In response, Incubate's executive director John Stanford warned that these demonstrations would have serious consequences for innovation: "Imposing price controls through mandatory Medicare demonstrations would impede scientific and medical progress. In sharp contrast to the voluntary pricing agreements recently struck by the Trump administration with individual companies, these far-reaching demonstrations would make funding life sciences research and development a much riskier and less attractive proposition for early-stage companies and their investors. "Pegging U.S. drug prices to those set by foreign governments increases uncertainty and weakens investor confidence, leading companies to reevaluate and scale back high-risk, high-impact research." Read the full statement here: https://lnkd.in/eGCiwpZk

🎙️A new episode of the Making Medicine podcast is out now! In this year-in-review episode, John Stanford looks back at the forces that shaped biotech in 2025 -- from major policy developments in Congress and the White House to shifting investment trends and what they mean for innovation and patients. 🏛️ The conversation covers defense-related biotech priorities, healthcare affordability debates, PBM reform efforts, and ongoing challenges around capital access for early-stage companies. 💰 Plus, hear takeaways from Incubate Policy Lab's analysis of 2025 biotech investment data, and learn which states crossed the $1 billion investment mark! 📺 Watch the full episode on YouTube: https://lnkd.in/eQMsR3KN 🎧 Follow Making Medicine Podcast for new episodes weekly.

🇺🇸🧬 Biotech isn’t just “health policy” anymore — it’s national security. 🎙️ On today’s new episode of the Making Medicine Podcast, we do a deep dive on the NDAA and what it means for early-stage biotechs, investors, and the broader innovation ecosystem. A few of our top takeaways: 🔬 Biology is now a strategic capability. The NDAA treats biomanufacturing, synthetic biology, and biological data the way we treat semiconductors and AI — core to U.S. national power. 🏛️ New doors at DoD (and beyond). A dedicated Biotechnology Management Office and new authorities to fund pilot plants and infrastructure could create real opportunities for dual-use platforms, secure biomanufacturing, and data tools. ⚠️ Tighter guardrails on China and “companies of concern.” Several provisions — including an updated BIOSECURE framework and new intelligence community role — mean more scrutiny on who you buy from, where your data live, and how cross-border partnerships are structured. 🌎💸 Outbound investment might be a focus in the future. Biotech isn’t formally in the new outbound investment regime yet, but the architecture is now in place, and life sciences will want to pay attention as rules evolve. 📈🔐 Net result: opportunity + constraint. There’s more potential capital and demand for trusted, U.S.-based biotech — alongside more compliance risk if you’re not thinking ahead about suppliers, data, and investors. 🎧 Listen to the full episode for the deep dive and what founders and VCs should be doing now: https://lnkd.in/gB_bkCfp 👇 If you have questions or want us to tackle a specific aspect of the NDAA in a future episode, drop them below. John Stanford John Guy Grace Moster #NDAA #biotech #lifesciences #china #investment

I was pleased to recently host Coke Morgan Stewart, Deputy Under Secretary of Commerce for Intellectual Property and Deputy Director of the U.S. Patent and Trademark Office (USPTO) and friend, author, and intellectual property advocate Jim Edwards. Thanks to the great group on-hand to launch Jim’s book “To Invent is Divine—Creativity and Ownership”.   Stewart (no relation) discussed the fundamental relationship between America’s strong property rights protections and our nation’s ability to attract foreign investment and promote domestic innovation. The U.S. must remain a durable and secure market that respects inventors and manufacturers. Our innovation economy is dependent on a USPTO that enforces the highest standards of IP rights. #Intellectualproperty #USPTO

💡 IP isn’t paperwork — it’s the foundation of every breakthrough. In this clip, Senator Thom Tillis explains why strong patents aren’t just a legal issue… they’re the fuel that keeps American innovation ahead of China, Europe, and the rest of the world. 🔬 Without reliable patents, early-stage science doesn’t get funded. 📉 Without funding, cures don’t get discovered. 🌎 Without U.S. leadership on IP, the global biotech race tilts away from us. If you care about discovery, competitiveness, and the future of medicine, this is the conversation to watch. 👉 Full episode now live: https://lnkd.in/e434yx8n Making Medicine Podcast John Guy John Stanford Grace Moster #Senate #IP #Investment #Biotech #Global #Competitiveness #Medicine #Patents

🎉 Making Medicine just crossed 500 YouTube subscribers! A huge thank you to everyone who’s tuned in, shared an episode, or joined us for conversations at the intersection of science, policy, and innovation. This year alone we’ve hosted leaders across IP, drug pricing, global competitiveness, Japan’s life-sciences boom, and now… our first U.S. Senator. And we’re just getting started. If you haven’t subscribed yet, join us here → https://lnkd.in/edmi2FXC Thanks for being part of the journey, and, as always, keep innovating. 🚀 John Stanford John Guy Grace Moster